SKB BIO-B (06990): The application for clinical trial of ITGB6 ADC SKB105 new drug has been approved by the National Medical Products Administration.

SKB BIO-B (06990) announced that the new drug clinical trial application (IND) for SKB105 (also known as CR-003), an antibody-drug conjugate (ADC) targeting integrin 6 (ITGB6) developed independently by the company, has been approved by the China National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) for the treatment of advanced solid tumors. In December 2025, the company entered into a strategic partnership with Crescent Biopharma, Inc. for SKB105/CR-003 and SKB118 (programmed cell death protein-1 (PD-1) x vascular endothelial growth factor (VEGF) bispecific antibody, also known as CR-001). The agreement grants Crescent exclusive rights to research, develop, manufacture, and commercialize SKB105/CR-003 in the United States, Europe, and all other major regions outside of Greater China (including mainland China, Hong Kong, Macau, and Taiwan), while the company is granted exclusive rights by Crescent to research, develop, manufacture, and commercialize SKB118/CR-001 in Greater China. The company plans to submit an IND application for SKB118/CR-001 to the China National Medical Products Administration Drug Evaluation Center in the near future.